CT-guided implantation of phosphorus-32 microparticles for non-progressive locally advanced pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses CT-guided intratumoural implantation of OncoSil™—a device with phosphorus-32–labeled microparticles—to deliver localized radiation inside the tumor. The aim is to assess safety and preliminary efficacy in adults with non-progressive locally advanced pancreatic cancer that is not resectable. Eligible participants have stable disease after chemotherapy and meet tumor size and health criteria, with ongoing monitoring for adverse effects and tumor response. The study spans phase 1 and phase 2 to establish safety and explore treatment signals before broader use.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years
* Locally advanced pancreatic cancer, defined by the DPCG consensus criteria as: arterial involvement \>90 degrees or venous involvement \>270 degrees.
* At least RECIST stable disease after a minimum two months of chemotherapy according to current clinical practice\*
* Capable of providing written and oral informed consent
* Candidate for RNT, judged by a multidisciplinary tumor board
* WHO 0-2

Exclusion Criteria:

* Eligibility for resection
* Participation in other trials focussing on different ablative treatment modalities such as radiofrequency ablation or irreversible electroporation for LAPC
* Known hypersensitivity to silicon or phosphor
* Bleeding disorders which cannot be corrected with medication
* Inability/unwillingness to interrupt anticoagulation therapy
* Pregnancy
* Metastatic pancreatic cancer
* Epilepsy episode(s) in the past six months
* Longest tumor diameter \>70 mm or total target tumor volume \>110 ml
* Presence of multiple collateral vessels surrounding or adjacent to the target tumor on radiologic imagining, prohibiting safe injection of the OncosilTM device
* Presence (or significant risk) of varices near the target tumor on radiologic imaging
* Recent clinically significant pancreatitis
* Previous administration of radiotherapy to the pancreas

Where it's running

• Amsterdam UMC - Location VUmc
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Study coordinator: Danielle J.W. Vos
• Email: d.vos@amsterdamumc.nl
• Phone: +31204444571

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

• Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer

  This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT07892573

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

• Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)

  This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.

  Recruiting Phase 1 Matter Bio, Inc. · The Bronx, New York · NCT07828236

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.